证券简称：圣达生物 证券代码：603079 浙江圣达生物药业股份有限公司 向特定对象发行A股股票 发行情况报告书 保荐人（主承销商） 二〇二五年六月 浙江圣达生物药业股份有限公司 向特定对象发行 A 股股票发行情况报告书 发行人全体董事、监事及高级管理人员声明 浙江圣达生物药业股份有限公司全体董事、监事及高级管理人员承诺本发行 情况报告书不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、 完整性承担相应的法律责任。 公司全体董事签名： 洪 爱 朱勇刚 陈不非 周 斌 徐建新 ZHU JING（朱静） 胡国华 李永泉 陈希琴 公司全体监事签名： 徐 涵 周娟娟 洪灿灿 公司全体非董事高级管理人员签名： ZHU JENNY YI-XUAN 庞 晗 许祥晓 （朱怡萱） 浙江圣达生物药业股份有限公司 年 月 日 浙江圣达生物药业股份有限公 司 向特定对象发行 A 股 票发行情况报告书 目 录 浙江圣达生物药业股份有限公司 向特定对象发行 A 股票发行情况报告书 释 义 在本发行情况报告书中，除非上下文另有所指，下列简称具有如下含义： 圣达生物、发行人、 指 浙江圣达生物药业股份有限公司 公司 本次发行、本次 ...

Core Viewpoint - The company is issuing shares to specific investors, which will dilute immediate returns but aims to enhance long-term competitiveness and financial stability through strategic investments in projects related to the automotive parts industry [2][3][6]. Financial Impact Analysis - The company plans to issue 244,149,936 shares, increasing total shares to 1,057,983,058 [4]. - The projected net profit for 2025 is estimated at 953 million yuan, with scenarios predicting stable, 10% growth, or 10% decline in net profit compared to 2024 [4][5]. - Basic earnings per share (EPS) before the issuance is projected at 1.13 yuan, which could drop to 0.87 yuan under stable profit conditions post-issuance [5][6]. Necessity and Reasonableness of the Issuance - The funds raised will be allocated to projects such as the Wuhu Automotive Parts Intelligent Manufacturing Project and the Chongqing Automotive Interior Parts Production Base, which align with the company's core business and future strategic layout [7][8]. - The issuance is deemed necessary to enhance the company's core competitiveness and sustainable development capabilities [6][8]. Relationship with Existing Business - The projects funded by the issuance are closely related to the company's main operations in automotive parts design, development, production, and sales [7]. - The company has a strong talent pool and technical capabilities to support the implementation of these projects, ensuring effective execution [8][9]. Measures to Mitigate Dilution of Immediate Returns - The company plans to enhance operational efficiency and reduce costs through optimized business processes and internal controls [10]. - Strict management of raised funds will be implemented to ensure they are used effectively and transparently, protecting the interests of small investors [10][11]. - The company will accelerate project construction to realize expected benefits quickly, thereby mitigating the dilution of immediate returns [10][11]. Commitments from Company Leadership - The board and senior management have committed to diligently executing measures to mitigate the impact of share issuance on immediate returns, ensuring accountability [12][13]. - The controlling shareholder and actual controller have also made commitments to uphold these measures and accept responsibility for any losses incurred due to non-compliance [13].

董事会公告 证券代码：002048 证券简称：宁波华翔 公告编号：2025-040 宁波华翔电子股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司全体董事、监事、高级管理人员保证公告内容真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 宁波华翔电子股份有限公司（以下简称"公司"）第八届董事会第二十次会议审 议通过了《关于召开2025年第二次临时股东大会的议案》 （以下简称"本次股东大会"）， 现就召开本次股东大会的相关事项通知如下： 一、召开会议的基本情况 公司法》《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公司章程》 的规定。 现场会议时间为：2025年7月7日（星期一）下午14：30； 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为： 券交易所互联网投票系统投票的具体时间为：2025年7月7日上午9：15至下午15：00期 间的任意时间。 东大会将通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络形式 的投票平台，股东可以在网络投票时间内通过上述系统行使表决权。 董事会公告 表决权出现重复表决的以第一次投票结果为准。 ...

证券代码：688378 证券简称：奥来德 公告编号：2025-037 吉林奥来德光电材料股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 吉林奥来德光电材料股份有限公司（以下简称"公司"）第五届董事会第十 三次会议于2025年6月13日在长春市高新开发区红旗大厦19层公司会议室以现场 结合通讯的方式召开。本次会议通知于2025年6月6日以专人送达等方式送达全体 董事。公司应参加董事共计9人，实际出席董事9人，会议由董事长轩景泉先生主 持，本次会议的召集、召开方式等符合《公司法》等法律法规、规范性文件及《公 司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于公司符合以简易程序向特定对象发行股票条件的议案》 本议案已经战略委员会/独立董事专门会议事先审议通过。 表决结果：同意9票，反对0票，弃权0票。 （二）审议通过《关于公司2025年度以简易程序向特定对象发行股票方案的 议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 表决结果：同意 9 票，反对 0 票，弃权 0 ...

Core Viewpoint - The independent directors of Ningbo Huaxiang held a special meeting to approve multiple proposals regarding the issuance of shares to specific targets, indicating the company's compliance with relevant laws and regulations, and affirming the benefits of the issuance for long-term development and shareholder interests [1][2][4][6][7]. Group 1: Approval of Stock Issuance Proposals - The independent directors unanimously agreed that the company meets the conditions for issuing shares to specific targets as per the Company Law and Securities Law [1]. - The proposed plan for issuing shares to specific targets was deemed feasible and beneficial for enhancing the company's core competitiveness and long-term development [1][2]. - The analysis report on the stock issuance plan was considered thorough and aligned with the company's actual situation, ensuring no harm to shareholders, especially minority shareholders [2][4]. Group 2: Fundraising and Usage Analysis - The feasibility analysis report for the use of funds raised through the stock issuance was approved, confirming alignment with national industrial policies and the company's growth strategy [4]. - The previous fundraising usage report was acknowledged as accurately reflecting the company's prior fundraising activities, providing transparency for investors [5]. Group 3: Measures and Authorizations - The company presented measures to address the dilution of immediate returns from the stock issuance, with commitments from relevant parties to ensure these measures are implemented [6]. - The proposal to authorize the board of directors to handle specific matters related to the stock issuance was approved, facilitating efficient execution of the issuance process [7]. - The decision to jointly invest in an industrial fund with professional investment institutions was supported, highlighting the strategic alignment with the company's business development and risk management [7].

根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理办 法》（以下简称"《注册管理办法》"）等法律法规以及《宁波华翔电子股份有 限公司章程》（以下简称"《公司章程》"）的相关规定，宁波华翔电子股份有 限公司（以下简称"公司"）第八届监事会在全面了解和审阅公司本次向特定对 象发行股票（以下简称"本次发行"）的相关文件后，发表书面审核意见如下： 法规、规章及规范性文件关于向特定对象发行股票的有关规定，具备向特定对象 发行股票的条件。 次募集资金的使用与管理严格遵循中国证券监督管理委员会（以下简称"中国证 监会"）、深圳证券交易所关于上市公司募集资金存放和使用的相关规定，已披 露的募集资金使用的相关信息真实、准确、完整，不存在变相改变募集资金投向、 损害股东利益等违规情形。 益，降低本次向特定对象发行股票摊薄公司即期回报的影响，公司制定了摊薄即 期回报的填补措施，公司控股股东、实际控制人、董事和高级管理人员就本次向 特定对象发行股票填补摊薄即期回报措施能够得到切实履行作出了相应承诺。 程序符合相关法律、法规及《公司章程》规定，形成的 ...

监事会决议公告 证券代码:002048 证券简称:宁波华翔 公告编号:2025-039 宁波华翔电子股份有限公司 二、监事会会议审议情况 经与会监事认真讨论，审议通过如下决议： 根据《公司法》《中华人民共和国证券法》（以下简称"《证券法》"）以及 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司证券发行注册管 理办法》（以下简称"《注册管理办法》"）等有关法律、法规和规章的规定，公 司监事会对照上市公司向特定对象发行股票的相关资格、条件的要求，经认真自查， 认为公司符合向特定对象发行股票的各项条件。 表决结果：3 票同意；0 票反对；0 票弃权。 本议案需提交公司股东大会审议。 本公司全体董事、监事、高级管理人员保证公告内容真实、准确和完整，并对 公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、监事会会议召开情况 宁波华翔电子股份有限公司（以下简称"公司"）第八届监事会第十四次会议 通知于 2025 年 6 月 3 日以邮件或传真的方式发出，会议于 2025 年 6 月 13 日下午 2 点在上海浦东以通讯方式召开。会议由监事会召集人於树立先生主持，会议应出席 监事 3 名，亲自出席监事 3 ...

Group 1 - The company, Shanxi Yongdong Chemical Co., Ltd., received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a private placement of shares on April 21, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough study and addressed the questions raised in the inquiry letter, with detailed responses disclosed on May 15, 2025 [1] - The company has made supplementary revisions to the response content and the prospectus based on further review opinions from the Shenzhen Stock Exchange [2] Group 2 - The private placement of shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] - The company will fulfill its information disclosure obligations in a timely manner based on the progress of this matter [2]

Core Viewpoint - The document outlines the underwriting and issuance process for Ningxia Yinglite Chemical Co., Ltd.'s stock issuance to specific investors, detailing the roles of the underwriters and the company's compliance with relevant regulations [1][18]. Group 1: Issuer Information - Ningxia Yinglite Chemical Co., Ltd. was established in November 1996 and is listed on the Shenzhen Stock Exchange under the stock code 000635 [5]. - The company has a registered capital of 303,486,737 RMB and operates in the chemical production sector, including hazardous chemicals and general chemical products [6][7]. Group 2: Underwriter Details - CITIC Securities is the underwriter for this issuance, with Yang Xuele and Xu Xingwen designated as the lead underwriters, both having extensive experience in managing public offerings [3][4]. - The underwriting team has a strong track record, having previously managed significant IPOs and private placements [3][4]. Group 3: Issuance Details - The issuance involves offering A-shares to no more than 35 specific investors, including the controlling shareholder, Yinglite Group [14][22]. - The pricing for the shares will be based on the average stock price over the 20 trading days prior to the issuance date, ensuring it does not fall below the net asset value per share [22]. Group 4: Financial Performance - As of March 31, 2025, the total assets of the company were reported at 266,184.15 million RMB, with total liabilities of 164,021.86 million RMB, indicating a debt ratio of approximately 61.62% [9][10]. - The company reported a net profit of -8,223.50 million RMB for the first quarter of 2025, reflecting ongoing financial challenges [10]. Group 5: Compliance and Governance - The underwriting process has undergone rigorous internal review and compliance checks, ensuring adherence to the Company Law and Securities Law of the People's Republic of China [11][15]. - The underwriter has committed to maintaining transparency and integrity throughout the issuance process, with no conflicts of interest identified [11][16].

Core Viewpoint - The company has adjusted the issuance price and quantity of A-shares for specific targets following the implementation of the 2024 annual equity distribution plan, with the price changing from 18.52 yuan/share to 18.23 yuan/share and the quantity increasing from a maximum of 21,598,272 shares to 21,941,854 shares [1][4]. Issuance Price and Quantity Adjustment - The adjustment of the issuance price and quantity was approved by the company's board of directors, supervisory board, and the shareholders' meeting [1][2]. - The adjusted issuance price is calculated by subtracting the cash dividend per share from the initial price, resulting in an adjusted price of 18.23 yuan/share [4]. - The maximum number of shares to be issued is now set at 21,941,854 shares, which is compliant with regulations as it does not exceed 30% of the company's total share capital prior to the issuance [4]. Equity Distribution Implementation - The 2024 annual equity distribution plan was approved on May 26, 2025, with a distribution of 3 yuan (including tax) per 10 shares, totaling a cash dividend of no more than 29,793,223.50 yuan [2][3]. - The equity distribution's record date is June 9, 2025, and the ex-dividend date is June 10, 2025 [3].